Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?

Mattia Novo, Grzegorz S. Nowakowski, Thomas M. Habermann, Thomas E. Witzig, Ivana N. Micallef, Patrick B. Johnston, David J. Inwards, Barbara Botto, Kay M. Ristow, Jason R. Young, Umberto Vitolo, Stephen M. Ansell

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Residual mediastinal FDG-uptake after frontline therapy for classical Hodgkin lymphoma (cHL) may constitute persistent disease or inflammatory changes. We analyzed practice patterns at two institutions to determine how often a mediastinal biopsy influenced patient management and outcome. Forty-two cases were eligible for review, mostly treated with ABVD. Twenty (group1) underwent a mediastinal biopsy and 22 did not (group2). In group1, 10/20 were positive for cHL and proceeded to salvage therapy (ST); 4/10 biopsy-negative patients were observed, and 6/10 received consolidative radiotherapy. Ten of 22 patients from group 2 were observed, 12/22 received ST. Ten of 14 observed patients remained PET-positive and 8/8 biopsies in these patients showed cHL. Deauville score (DS) 5 was associated with a positive biopsy (10/16). No overall survival difference between groups was observed. We conclude that observation and repeat a FDG-PET is reasonable for DS3-4 while for DS5, ST should be considered pending biopsy confirmation when feasible.

Original languageEnglish (US)
Pages (from-to)318-327
Number of pages10
JournalLeukemia and Lymphoma
Volume61
Issue number2
DOIs
StatePublished - Jan 28 2020

Keywords

  • ABVD
  • Deauville score
  • FDG-PET
  • Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?'. Together they form a unique fingerprint.

  • Cite this